AMP2018 Abstract: KRAS Mutations in Tissue Samples from Cologuard-Positive Patients

Kathleen Murphy, Ph.D., ProPath Chief Laboratory Officer and Director of Molecular Diagnostics

Abstract research by Kathleen Murphy, Ph.D., Chewlan Lastufka, Katherine Wicks, Angela R. Lewis, Kristina Weatherhead, Ashley Fratto, Caryn A. Pirtle, Chris Fourment, M.D., Timothy Ritter, M.D., Alex Pieper, Cory Roberts, M.D., ProPath Research and the Texas Digestive Disease Consultants

The ProPath Molecular Oncology Lab, in collaboration with TDDC, performed a research study evaluating biopsy specimens from patients that tested positive by the cologuard colon cancer screening test. The study demonstrated that relatively few (16%) biopsies had mutations in the KRAS gene. These findings suggest that DNA mutation analysis contributes relatively little to the sensitivity of the cologuard test. The results were presented at the 2018 annual meeting of the Association of Molecular Pathology in San Antonio, Texas.